Cargando…

Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia

PURPOSE: The purpose of this study was to describe the association between adherence to antipsychotic medication and quality of life (QoL) in a sample of individuals diagnosed with schizophrenia. METHODS: Two hundred fifty-three patients were included from three public mental health services from Bo...

Descripción completa

Detalles Bibliográficos
Autores principales: Caqueo-Urízar, Alejandra, Urzúa, Alfonso, Mena-Chamorro, Patricio, Fond, Guillaume, Boyer, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481279/
https://www.ncbi.nlm.nih.gov/pubmed/32943851
http://dx.doi.org/10.2147/PPA.S265312
_version_ 1783580566573023232
author Caqueo-Urízar, Alejandra
Urzúa, Alfonso
Mena-Chamorro, Patricio
Fond, Guillaume
Boyer, Laurent
author_facet Caqueo-Urízar, Alejandra
Urzúa, Alfonso
Mena-Chamorro, Patricio
Fond, Guillaume
Boyer, Laurent
author_sort Caqueo-Urízar, Alejandra
collection PubMed
description PURPOSE: The purpose of this study was to describe the association between adherence to antipsychotic medication and quality of life (QoL) in a sample of individuals diagnosed with schizophrenia. METHODS: Two hundred fifty-three patients were included from three public mental health services from Bolivia, Peru, and Chile. Data were collected using the Drug Attitude Inventory (DAI-10) and the Schizophrenia Quality of Life short-version questionnaire (SQoL-18), which considers 8 dimensions. RESULTS: Significant associations were found between adherence to antipsychotic medication treatment and QoL (S-QoL-18 index: β = 0.26, p = 0.004; self-esteem: β = 0.37, p = 0.000; and sentimental life: β = 0.20, p = 0.033). Associations of clinical and socio-demographic variables with QoL were identified: severity of psychotic symptoms, awareness of the disease, gender, age, and ethnicity were found to be associated with a lower level of QoL (β from 0.14 −0.56). CONCLUSION: This study provides evidence of the association between adherence to treatment and quality of life in patients diagnosed with schizophrenia. Therefore, as in developed countries, improving adherence to antipsychotic medication would appear to be an important issue to address to improve patients’ QoL in Latin American countries.
format Online
Article
Text
id pubmed-7481279
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-74812792020-09-16 Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia Caqueo-Urízar, Alejandra Urzúa, Alfonso Mena-Chamorro, Patricio Fond, Guillaume Boyer, Laurent Patient Prefer Adherence Original Research PURPOSE: The purpose of this study was to describe the association between adherence to antipsychotic medication and quality of life (QoL) in a sample of individuals diagnosed with schizophrenia. METHODS: Two hundred fifty-three patients were included from three public mental health services from Bolivia, Peru, and Chile. Data were collected using the Drug Attitude Inventory (DAI-10) and the Schizophrenia Quality of Life short-version questionnaire (SQoL-18), which considers 8 dimensions. RESULTS: Significant associations were found between adherence to antipsychotic medication treatment and QoL (S-QoL-18 index: β = 0.26, p = 0.004; self-esteem: β = 0.37, p = 0.000; and sentimental life: β = 0.20, p = 0.033). Associations of clinical and socio-demographic variables with QoL were identified: severity of psychotic symptoms, awareness of the disease, gender, age, and ethnicity were found to be associated with a lower level of QoL (β from 0.14 −0.56). CONCLUSION: This study provides evidence of the association between adherence to treatment and quality of life in patients diagnosed with schizophrenia. Therefore, as in developed countries, improving adherence to antipsychotic medication would appear to be an important issue to address to improve patients’ QoL in Latin American countries. Dove 2020-09-03 /pmc/articles/PMC7481279/ /pubmed/32943851 http://dx.doi.org/10.2147/PPA.S265312 Text en © 2020 Caqueo-Urízar et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Caqueo-Urízar, Alejandra
Urzúa, Alfonso
Mena-Chamorro, Patricio
Fond, Guillaume
Boyer, Laurent
Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia
title Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia
title_full Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia
title_fullStr Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia
title_full_unstemmed Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia
title_short Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia
title_sort adherence to antipsychotic medication and quality of life in latin-american patients diagnosed with schizophrenia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481279/
https://www.ncbi.nlm.nih.gov/pubmed/32943851
http://dx.doi.org/10.2147/PPA.S265312
work_keys_str_mv AT caqueourizaralejandra adherencetoantipsychoticmedicationandqualityoflifeinlatinamericanpatientsdiagnosedwithschizophrenia
AT urzuaalfonso adherencetoantipsychoticmedicationandqualityoflifeinlatinamericanpatientsdiagnosedwithschizophrenia
AT menachamorropatricio adherencetoantipsychoticmedicationandqualityoflifeinlatinamericanpatientsdiagnosedwithschizophrenia
AT fondguillaume adherencetoantipsychoticmedicationandqualityoflifeinlatinamericanpatientsdiagnosedwithschizophrenia
AT boyerlaurent adherencetoantipsychoticmedicationandqualityoflifeinlatinamericanpatientsdiagnosedwithschizophrenia